Ergomed (LON:ERGO) Downgraded to “Hold” at Shore Capital

Shore Capital downgraded shares of Ergomed (LON:ERGOFree Report) to a hold rating in a research report report published on Monday morning, MarketBeat reports.

Separately, Berenberg Bank reissued a buy rating and issued a GBX 1,450 ($18.31) target price on shares of Ergomed in a research report on Tuesday, July 25th.

Read Our Latest Stock Report on Ergomed

Ergomed Stock Up 28.1 %

Shares of LON:ERGO opened at GBX 1,348 ($17.02) on Monday. Ergomed has a 52-week low of GBX 895 ($11.30) and a 52-week high of GBX 1,380 ($17.43). The firm has a market capitalization of £684.92 million, a P/E ratio of 4,493.33 and a beta of 0.83. The stock has a 50 day moving average price of GBX 1,043.35 and a 200-day moving average price of GBX 1,043.82. The company has a debt-to-equity ratio of 3.43, a quick ratio of 1.22 and a current ratio of 1.50.

Ergomed Company Profile

(Get Free Report)

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance.

Featured Stories

Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with's FREE daily email newsletter.